Reuters: Genentech drug boosts leukemia patient survival

[NaDiNe]

Genentech drug boosts leukemia patient survival
      

LOS ANGELES (Reuters) - A combination of Genentech Inc's cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday.<div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login